Clinical Trial

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 5, 2025 (before its estimated March 25, 2026 completion). Its status may not reflect the trial's current state.
Summary
This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes according to the primary and secondary endpoints.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-16.
Trial Details
NCT Number NCT06374602
Lead Sponsor Saint Petersburg State University, Russia
Conditions Anaplastic Thyroid Cancer
Enrollment 20 participants
Start Date 2024-03-25
Primary Completion 2026-03-25 (estimated)
Study Completion 2026-06-25 (estimated)
Updated on ClinicalTrials.gov 2025-09-05